You make the discovery. We help make it reality.
Transforming the CDMO experience.
Unrivaled expertise. World-class facilities. Exceptional quality. Personalized process. This is how your molecule becomes a cure impacting millions of lives.
You make the discovery. We make it reality.
Transforming the CDMO experience.
Unrivaled expertise. World-class facilities. Exceptional quality. Personalized process. This is how your molecule becomes a cure impacting millions of lives.
You make the discovery. We make it reality.
Transforming the CDMO experience.
Unrivaled expertise. World-class facilities. Exceptional quality. Personalized process. This is how your molecule becomes a cure impacting millions of lives.
You make the discovery. We help make it reality.
Transforming the CDMO experience.
Unrivaled expertise. World-class facilities. Exceptional quality. Personalized process. This is how your molecule becomes a cure impacting millions of lives.
From concept to market, we’re your advocate.
To us, it’s personal.
Our community is made up of brilliant thinkers, good listeners, and problem solvers. We’re the people you want on your team at every stage. That’s the Avid effect.
CDMO solutions tailored for you.
Bringing 30+ years of experience manufacturing biologics.
Mammalian Protein Development & Manufacturing
With an unparalleled track record for quality and late-stage expertise, we’re the only CDMO that will treat your molecule like it’s our own.
Case Study
Optimizing Production and Accelerating the Timeline from Cell Line Development to CGMP Production
This case study highlights how Avid Bioservices leveraged decades of expertise, broad capabilities, and comprehensive knowledge of regulatory requirements to implement effective strategies and solutions.
Q&A
Navigating New U.S. Onshoring & Pharmaceutical Tariff Developments
A Q&A with Kenneth Bilenberg, Group President & CEO of Avid Bioservices. Recently, the U.S. Department of Commerce released procedures allowing pharmaceutical companies to apply for company-specific tariff adjustments tied to U.S. onshoring commitments and domestic manufacturing investments.
EBook
Quality by Design: How modern CDMOs build robust processes, analytical control, and regulatory confidence across the biologics lifecycle
Building quality and control from development to commercialization
Case Study
Optimizing Production and Accelerating the Timeline from Cell Line Development to CGMP Production
INSIDE THE SCIENCE
Conversations with Avid Experts: Building High-Performing Cell Lines for Biologic Therapies
This case study highlights how Avid Bioservices leveraged decades of expertise, broad capabilities, and comprehensive knowledge of regulatory requirements to implement effective strategies and solutions.
Success STORY
Seamless Onshoring from China-based CDMO to Avid Bioservices – Achieving a Titer of 5.2 g/L
A U.S.-based biotechnology company sought to relocate its manufacturing program from a China-based CDMO to a trusted U.S. Partner.
Video
Take a virtual peek behind the curtain.
Our state-of-the-art Myford DS Line 3 facility is fully equipped to deliver high-quality CGMP mammalian protein products — see inside with our virtual tour.
Whitepaper
DNA to IND: An Early Phase Playbook for how to Build a CMC Strategy That Enables Fast IND
How to Build a CMC Strategy That Enables Fast IND Without Rework Later. A Practical Framework for Early-Phase Programs Selecting the Right CDMO Partner
Q&A
Navigating New U.S. Onshoring & Pharmaceutical Tariff Developments
A Q&A with Kenneth Bilenberg, Group President & CEO of Avid Bioservices. Recently, the U.S. Department of Commerce released procedures allowing pharmaceutical companies to apply for company-specific tariff adjustments tied to U.S. onshoring commitments and domestic manufacturing investments.
EBOOK
Quality by Design: How modern CDMOs build robust processes, analytical control, and regulatory confidence across the biologics lifecycle
Building quality and control from development to commercialization
INSIDE THE SCIENCE
Conversations with Avid Experts: Building High-Performing Cell Lines for Biologic Therapies
Cell line development (CLD) is one of the earliest—and most consequential—steps in biologics manufacturing. It establishes the cellular foundation that will produce the therapeutic protein throughout development, clinical manufacturing, and ultimately commercial production.
SUCCESS STORY
Seamless Onshoring from China-based CDMO to Avid Bioservices – Achieving a Titer of 5.2 g/L
A U.S.-based biotechnology company sought to relocate its manufacturing program from a China-based CDMO to a trusted U.S. Partner.
White Paper
DNA to IND: An Early Phase Playbook for how to Build a CMC Strategy That Enables Fast IND
How to Build a CMC Strategy That Enables Fast IND Without Rework Later. A Practical Framework for Early-Phase Programs Selecting the Right CDMO Partner